secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001493152-24-018242
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intelligent Bio Solutions Q3 revenue up 80% to $0.82M; cash $9.4M after $10.76M capital raise
--------------------------------------------------------------------------------

- Revenue of $0.82M for Q3 FY2024, up 80% YoY; nine-month revenue $2.38M, up 193%.
- Net loss for Q3 was $2.98M, including $0.54M non-cash items; nine-month net loss decreased to $7.37M.
- Cash and equivalents $9.4M as of March 31, 2024, up from $1.1M at Dec 31, 2023, after net capital raise of ~$10.76M.
- FDA 510(k) clinical studies with Cliantha Research underway; submission expected by end of 2024, US entry planned in 2025.
- Secured 26 new accounts during quarter, representing ~16,779 employees; European patent granted for DSR-Plus Cartridge Reader.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/0001493152-24-018242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315224018242/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer